It once had an FDA-approved label — and then the product disappeared from the market. Here's what sermorelin actually is, why its approval status is more complicated than the marketing suggests, what the science does and doesn't show, and exactly where it stands in 2026.
Sermorelin (also called sermorelin acetate, or GRF 1–29) is a synthetic analog of growth-hormone-releasing hormone (GHRH) — specifically the first 29 amino acids of GHRH, which is the active portion. Instead of being growth hormone itself, it works one step upstream: it signals the pituitary gland to release the body's own growth hormone in a natural, pulsatile pattern. That mechanism is the whole reason it gets attention in anti-aging and wellness circles.
The honest headline: sermorelin has a real clinical history — unlike many research peptides, it was once an FDA-approved drug — but the marketed product is gone, and the popular anti-aging uses you'll see promoted today are largely off-label and not well supported by rigorous human trials. That gap between a discontinued legacy approval and today's wellness marketing is exactly what this page exists to close.
This is where the nuance really matters, because "sermorelin was FDA-approved" is technically true and badly misleading at the same time:
Want the live picture? Our regulatory-status tracker shows exactly where sermorelin and other peptides stand right now, with the dated primary sources.
Sermorelin's strongest evidence sits in its original clinical role: as a GHRH analog it reliably stimulates the pituitary to release growth hormone, which is why it was historically used to assess and treat growth-hormone deficiency. The mechanism is well characterized.
The popular anti-aging, body-composition, and "longevity" claims are a different story. Human clinical evidence for those uses is limited, and much of what circulates online is anecdote rather than controlled data. That doesn't mean it "does nothing" — it means the evidence needed to say it delivers those benefits safely, in healthy adults, largely isn't there yet. Treat confident before-and-after claims with skepticism.
Because there is no currently-marketed FDA-approved sermorelin product, there is no official consumer dosing on a current label. Commonly reported subcutaneous doses sit around 0.1–0.3 mg (100–300 mcg) per day, often taken at night to mirror natural growth-hormone pulses. To be clear: these are not approved or standardized doses — they reflect what clinics and the wider community commonly report using today, shared for education, not medical advice. Any decision belongs with a licensed provider.
Sermorelin typically ships as a freeze-dried (lyophilized) powder that must be reconstituted with bacteriostatic water before it's a liquid. The math — concentration and the volume to draw — trips a lot of people up, and a misplaced decimal in micrograms is a 1,000× error. That's what our free tool is for:
From its clinical history, commonly reported effects are mild and local — for example, redness, swelling, or irritation at the injection site — along with occasional flushing, headache, or dizziness. Because it raises growth-hormone signaling, the same cautions that apply to growth-hormone therapy are worth weighing with a provider. Long-term safety of the modern compounded and research-use-only supply is not well established, and product quality varies enormously between sources. Because much of today's supply is compounded or research-use-only and not FDA-approved, purity, sterility, and accurate labeling are real concerns — which is why sourcing and testing matter as much as the molecule itself.
If you're considering sermorelin, the responsible path runs through a licensed provider who can weigh your situation, not a checkout page. Questions worth asking: Is it being compounded by a licensed pharmacy, or is this research-use-only material? Is there third-party testing and a certificate of analysis? What's the source and is it disclosed? What does the provider make of the current legal status given the product's discontinuation? This isn't legal or medical advice — it's the baseline diligence any unapproved or compounded substance deserves.
No. HGH (human growth hormone) is the hormone itself. Sermorelin is a GHRH analog that prompts your own pituitary to release growth hormone — it works upstream rather than supplying the hormone directly.
A branded product (Geref) was approved in the 1990s, but the manufacturer discontinued it in 2008. There is no currently-marketed FDA-approved sermorelin product today; it's available via compounding pharmacies or sold research-use-only. A discontinued approval is not a current approval.
All aim to raise growth-hormone signaling, but by different routes. Sermorelin and CJC-1295 are GHRH analogs; ipamorelin is a ghrelin-receptor (secretagogue) peptide. We cover CJC-1295 and ipamorelin separately in the library; the same caveats about limited human evidence apply.
We don't sell peptides and we don't direct consumers to buy unapproved substances. If a licensed provider determines it's appropriate, compounding source and testing should be part of that conversation.
Educational information only. Not medical, legal, or regulatory advice, not a dosing, treatment, or efficacy claim, and not a recommendation to obtain or use any substance. Many peptides are not FDA-approved; some are labeled research-use-only ("not for human use"). Regulatory status changes frequently — verify independently and consult a licensed provider before any health decision. Published by Health Pro Distributors. © 2026.